A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1

British Journal of Cancer

Volumn 94, Issue 10, 2006, Pages 1504-1509

  Newton, R ^a,b   Carpenter, L ^c   Casabonne, D ^b   Beral, V ^b   Babiker, A ^d   Darbyshire, J ^d   Weller, I ^d   Weiss, R ^d   Kwan, A ^e   Bourboulia, D ^e   Munoz, F ^e   Lagos, D ^e   Boshoff, C ^e  

^a Epidemiology and Genetics Unit   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Epstein Barr virus; Human immunodeficiency virus; Kaposi's sarcoma; Kaposi's sarcoma associated herpesvirus; Non Hodgkin's lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER RISK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROSPECTIVE STUDIES; SARCOMA, KAPOSI; TUMOR CELLS, CULTURED;

EID: 33646834925     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603100     Document Type: Article

References (23)

1. Akre O, Lipworth L, Tretli S, Linde A, Engstrand L, Adami HO, Melbye M Andersen A, Ekbom A (1999) Epstein Barr virus and cytomegalovirus in relation to testicular cancer risk: a nested case-control study. Int J Cancer 82: 1-5
2. Alpha International Co-ordinating Committee (1996) The Alpha Trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. AIDS 10: 867-880
3. Beral V, Newton R (1998) Overview of the epidemiology of immunodeficiency associated cancers. Monogr Natl Cancer Inst 23: 1-6
4. Berrington de Gonzalez A, Urban MI, Sitas F, Blackburn N, Goodhill A, Hale M, Patel M, Ruff P, Sur R, Newton R, Beral V (submitted) Antibodies against six human herpesviruses in relation to seven cancers in black South Africans
5. Boshoff C (1999) Kaposi's sarcoma associated herpesvirus. In Cancer Surveys Volume 33, Infections and Human Cancer, Newton R, Beral V, Weiss R (eds) Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press
6. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, Copas A, Boshoff C (2004) Short and long-term effects of highly active antiretroviral therapy of Kaposi's sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18: 485-493
7. Brooks LA, Crook T, Crawford DH (1999) Epstein Barr virus and lymphomas. In Cancer Surveys Volume 33, Infections and Human Cancer, Newton R, Beral V, Weiss R (eds) Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press
8. Concorde Co-ordinating Committee (1994) Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343: 871-881
9. Davidovici B, Karakis I, Bourboulia D, Ariad S, Zong JC, Benharroch D, Dupin N, Weiss R, Hayward G, Sarov B, Boshoff C (2001) Seroepidemiology and molecular epidemiology of Kaposi's sarcoma-associated herpesvirus among Jewish population groups in Israel. J Natl Cancer Inst 93: 194-202
10. Delta Co-ordinating Committee (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine and zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283-291
11. Hinuma Y, Konn M, Yamaguchi J, Wudarski DJ, Blakeslee JR, Grace JT (1967) Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol 1: 1045-1051
12. Jacobson LP, Jenkins FJ, Springer G, Muñoz A, Shah KV, Phair J, Zhang Z-F, Armenian H, for the Multicenter AIDS Cohort Study (2000) Interaction of human immunodeficiency virus 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Iinvest Dermatol 181: 1940-1949
13. Lam LL, Pau CP, Dollard SC, Pellett PE, Spirar TJ (2002) Highly sensitive assay for human herpesvirus 8 antibodies that uses multiple antigenic peptide derived from open reading frame K8.1. J Clin Micorbiol 40: 325-329
14. Lehtinen T, Lumio J, Dillner J, Hakama M, Knekt P, Lehtinen M, Teppo L, Leinikki P (1993) Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies - a prospective study. Cancer Causes Control 4: 187-192
15. Mueller N, Mohar A, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J (1991) Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma. Int J Cancer 49: 387-393
16. Newton R, Beral V, Weiss R (1999) Human immunodeficiency virus infection and cancer. In Cancer Surveys. Volume 33, Infections and Human Cancer, Newton R, Beral V, Weiss R (eds). Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press
17. Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter C, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, the Uganda Kaposi's Sarcoma Study Group, Weiss R, Boshoff C (2003b) Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda. Br J Cancer 89: 502-504
18. Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, the Uganda Kaposi's Sarcoma Study Group, Weiss R, Boshoff C (2003a) The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus in adults with cancer, in Uganda. Int J Cancer 103: 226-232
19. Renwick N, Halaby T, Weverling GJ, Dukers NH, Simpson GR, Coutinho RA, Lange JM, Schulz TF, Goudsmit J (1998) Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 12: 2481-2488
20. Rezza G, Andreoni M, Dorrucci M, Pezzotti P, Monini P, Zerboni R, Salassa B, Colangeli V, Sarmati L, Nicastri E, Barbanera M, Pristera R, Aiuti F, Ortona L, Ensoli B (1999) Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst 91: 1468-1474
21. Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D, Patel M, Ruff P, Bezwoda WR, Hale M, Jentsh U, Retter E, Pacella-Norman R, Bourboulia D, Whitby D, Boshoff C, Weiss R (1999) The seroepidemiology of HHV-8/KSHV in a large population of black cancer patients in South Africa. N Eng J Medicine 340: 1863-1871
22. de-Thé, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W (1978) Epidemiological evidence for a causal relationship between the Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274: 756-761
23. Ziegler J, Newton R, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Wabinga H, Mbulaiteye S, Jaffe H, the Uganda Kaposi's Sarcoma Study Group, Weiss R, Boshoff C (2003) Risk factors for Kaposi's sarcoma: a case-control study of HIV seronegative people in Uganda. Int J Cancer 103: 233-240